[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Azienda Ospedaliero-Universitaria di Parma\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":361},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,53,80,100,132,161,196,226,248,277,300,333],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100617070","comparison-of-self-locking-versus-traditional-sutures-in-double-layer-laparoscopic-vaginal-vault-closure-after-hysterectomy-bi-sure-trial-100617070",false,"NCT07313839","Comparison of Self-Locking Versus Traditional Sutures in Double-Layer Laparoscopic Vaginal Vault Closure After Hysterectomy (BI-SURE Trial)","Comparison Between Double-Layer Self-Locking and Traditional Sutures in Post-Hysterectomy Laparoscopic Colporrhaphy: A Multicenter Pragmatic Randomized Controlled Trial","BI-SURE","Inclusion Criteria:\n\n* Patients undergoing laparoscopic or robotically assisted hysterectomy for gynecologic malignant disease\n* Age ≥ 18 years\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Laparotomic or vaginal hysterectomy\n* Contraindication to laparoscopic vaginal vault closure","FEMALE","18 Years",{"count":20,"type":21},310,"ESTIMATED","INTERVENTIONAL",[24],"NA","Vaginal vault closure after laparoscopic or robotic hysterectomy may be associated with postoperative complications such as vaginal cuff dehiscence, infection, and bleeding. The optimal suture material and technique for laparoscopic colporrhaphy, particularly in patients undergoing surgery for gynecologic malignancies, remain controversial.\n\nThe BI-SURE trial is a multicenter, randomized controlled study designed to compare double-layer self-locking sutures versus double-layer traditional Polyglactin 910 sutures for laparoscopic vaginal vault closure after hysterectomy. The study aims to evaluate postoperative effectiveness and safety within three months after surgery.",[27,28,29],"Gynecologic Cancers","Vaginal Cuff Dehiscence","Postoperative Complications",[31,32,33,34,35,36,37,38,39],"Laparoscopic hysterectomy","Vaginal vault closure","Colporrhaphy","Self-locking suture","Barbed suture","Polyglactin 910","Gynecologic oncology","Postoperative complications","Randomized controlled trial","RECRUITING","2026-06-16",{"date":43,"type":44},"2026-06-17","ACTUAL",{"date":46,"type":44},"2025-10-07",{"date":48,"type":21},"2027-01",{"name":50,"class":51},"Azienda Ospedaliero-Universitaria di Parma","OTHER",5,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100627234","chemogenomic-profiling-in-hematological-malignancies-hem-profiling-2021-100627234","NCT07445984","Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)","Inclusion Criteria:\n\n* Patient aged \\>1 year old, referred for evaluation to the University Hospital of Parma;\n* Retrospective study: previously patients with hematological malignancies;\n* Prospective study: 1) patients with clinical suspect of hematological malignancies which requires a diagnostic assessment using peripheral blood drawn, bone marrow aspirate\u002Fbiopsy, lymph nodes biopsies or biopsies of tissues with metastatic involvement including liquor from rachicentesis, tissue aspirate etc. 2) patients with clinical suspect of relapsed\u002Frefractory onco-hematological disorder, which requires a diagnostic assessment using bone marrow aspirate\u002Fbiopsy or biopsies of tissues with metastatic involvement including lymph nodes, liquor from rachicentesis, tissue aspirate etc. 3) patients that progress in blastic transformation from a chronic condition or suspect of relapsed\u002Frefractory hematological disease, which requires a diagnostic assessment using peripheral blood drawn, bone marrow aspirate\u002Fbiopsy, lymph nodes biopsies or biopsies of tissues with metastatic involvement including liquor from rachicentesis, tissue aspirate etc;\n* Written informed consent. Retrospective study: informed consent will be signed during the first follow-up visit.\n\nExclusion Criteria:\n\n* Age \\\u003C1 year old\n* Patients who are unable to provide informed consent prior to any procedure for any reason.","ALL","1 Year",{"count":62,"type":21},250,[24],"The study will be conducted retrospectively and prospectively, using bone marrow (BM) or peripheral blood (PB) samples or biopsies of lymph nodes or tissues with metastatic involvement taken from previously stored samples here at the University Hospital of Parma or taken from patients that need to underwent diagnostic evaluation for a suspect or a defined diagnosis of hematological malignancies collected at the University Hospital of Parma.",[66,67,68,69,70],"Chronic Leukemia","Acute Leukemia","Myeloproliferative Disorders","Lymphoproliferative Disorders","Myelodysplastic Disorders","2026-02-25",{"date":73,"type":44},"2026-03-03",{"date":75,"type":44},"2021-07-28",{"date":77,"type":21},"2026-07-28",{"name":50,"class":51},1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":59,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":79},"100627192","feasibility-of-a-multi-omics-platform-for-hematological-malignancies-100627192","NCT07445438","Feasibility of a Multi-omics Platform for Hematological Malignancies","FOCUS","Inclusion Criteria:\n\n* Patient aged \\> 2 year old\n* Retrospective study:\n* Patients previously diagnosed with hematological malignancies\n* Prospective study:\n* Patients with clinical suspect of hematological malignancies requiring a diagnostic assessment using BM or PB samples, biopsies of lymph nodes or tissues with metastatic involvement, or other biological fluids (such as CSF, pathologic pleural effusion).\n* Patients with clinical suspicion of R\u002FR onco-hematological disorder, requiring a diagnostic assessment using BM aspirate\u002Fbiopsy or biopsies of tissues with metastatic involvement including lymph nodes, liquor from lumbar puncture, tissue aspirate etc.\n* Patients with blastic transformation from a chronic condition or suspect of R\u002FR hematological disease requiring a diagnostic assessment using PB drawn, BM aspirate\u002Fbiopsy, lymph nodes biopsies, or biopsies of tissues with metastatic involvement, including CSF from lumbar puncture, tissue aspirate, etc.\n\nExclusion Criteria:\n\n* Age \\\u003C2 year old\n* Patient without a diagnosis of hematological malignancy.","2 Years",{"count":89,"type":21},1040,[24],"This is a biological study based on a collaborative effort involving several Italian haematology centres (including the coordinating centre). The study will be conducted retrospectively and prospectively using bone marrow (BM) or peripheral blood (PB) samples, lymph node or tissue biopsies with metastatic involvement, and other biological fluids, such as cerebrospinal fluid and pathological pleural effusion.",[93,66,67,68,69,70],"Myeloma Multiple",{"date":73,"type":44},{"date":96,"type":44},"2025-03-31",{"date":98,"type":21},"2030-03",{"name":50,"class":51},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":79},"100625172","a-new-diagnostic-algorithm-to-non-invasively-track-fibrotic-changes-in-myeloproliferative-neoplasms-based-on-c-c-chemokine-receptor-2-detection-from-flow-cytometry-to-the-development-of-targeted-positron-emission-tomography-molecular-imaging-pre-clinical-studies-and-first-in-human-proof-of-concept-100625172","NCT07419178","A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept","GR-MPN","Inclusion Criteria:\n\n* Diagnosis of ET\u002FPV\u002FprePMF\u002FovertPMF according to the WHO 2016 criteria and of SMF according to the IWG-MRT criteria (with histopathological data).\n* Age \\>= 18 yrs\n* ECOG performance status \\\u003C=3\n\nExclusion Criteria:\n\n* Pregnancy\u002Fbreastfeeding\n* Ongoing therapy with immunomodulatory drugs (JAK-inhibitors, interferon).\n* For PET imaging, patients should be off any cytoreductive treatment for at least 3 months.\n* Antiplatelet agents are allowed",{"count":108,"type":21},265,[24],"Chronic \"Philadelphia-negative\" myeloproliferative syndromes are chronic blood disorders. They include essential thrombocythemia, polycythemia vera, and myelofibrosis. Myelofibrosis may arise de novo (\"primary myelofibrosis\") or represent the evolution of essential thrombocythemia or polycythemia vera (\"secondary myelofibrosis\").\n\nThe myelofibrotic stage-characterized, as the name implies, by the presence of bone marrow fibrosis (deposition of scar-like tissue)-is generally associated with a more severe and symptomatic disease. To date, the only way to assess fibrotic progression in these disorders is bone marrow biopsy.\n\nThe aim of this project is to evaluate whether the identification, tracking, and quantification of cells expressing a specific receptor (CCR2), a selective biomarker of fibrosis, may allow early and non-invasive identification of the fibrotic stage of the disease through:\n\n* laboratory analysis on a blood sample (using flow cytometry)\n* use in PET-CT (positron emission tomography combined with computed tomography) of a tracer specific for the CCR2 receptor, capable of selectively binding to CCR2-expressing cells (⁶⁸Ga-DOTA-ECL1i).",[112],"Myelofibrosis (MF)",[114,115,116,117,118,119,120,121,122,123],"C-C chemokine receptor 2","Myeloproliferative neoplasms","PET","immunohystochemical assay","early detection of cancer","progression monitoring","therapy response monitoring","MRI","MRS","fluorescence","2026-02-16",{"date":126,"type":44},"2026-02-18",{"date":128,"type":44},"2023-09-05",{"date":130,"type":21},"2027-04-30",{"name":50,"class":51},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},"100623976","integrative-multi-omics-and-functional-platform-for-the-complete-diagnostic-characterization-of-tumors-the-italian-tumor-chemogenomic-profiler-it-tcp-100623976","NCT07403630","INTEGRATIVE \"MULTI-OMICS\" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)","IT-TCP POS","Inclusion criteria:\n\n* Patients aged one year and over who are referred to the centres involved in the protocol (Azienda Ospedaliero-Universitaria di Parma, University of Parma, University of Perugia and Azienda Ospedali Riuniti Villa Sofia-Cervello of Palermo).\n* Patients with an established diagnosis of haematological or solid organ malignancy, including haematological or solid malignancies characteristic of the paediatric age group.\n* Patients diagnosed with relapsed, refractory and\u002For metastatic haematological or solid malignancy. Patients may be enrolled regardless of the extent and type of previous therapy. Patients may also be enrolled if they are undergoing active treatment at the time of evaluation.\n* Patients must have the capacity to understand the investigative nature of the study and provide informed consent in writing. For patients under the age of 12 years, consent will be provided by the parent\u002Flegal guardian according to international guidelines. For patients aged 12 to 17 years, consent will be provided by the patient and the parent\u002Flegal guardian according to the mature minor principle.\n\nExclusion criteria:\n\n* Patients younger than 1 year old\n* Patients with active, uncontrolled infections",{"count":140,"type":21},300,[24],"This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk. The study will be prospective, based on the consecutive enrollment of eligible patients at each participating institution.",[67,144,145,146,147,148,149,150,151,66,68,70],"Multiple Myeloma","Squamous Cell Carcinoma","Pleural Mesothelioma","Pancreatic Cancer","Bladder Cancer","Ovarian Cancer","Melanoma","Pediatric Acute Lymphoblastic Leukemia","2026-02-13",{"date":154,"type":44},"2026-02-17",{"date":156,"type":44},"2023-05-31",{"date":158,"type":21},"2028-02-12",{"name":50,"class":51},2,{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":168,"sex":59,"minAge":4,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":179,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":79},"100620649","interprofessional-collaboration-in-the-cardiac-intensive-care-unit-cicu-an-action-research-training-project-100620649","NCT07360366","Interprofessional Collaboration in the Cardiac Intensive Care Unit (CICU): An Action-Research Training Project","COLLUTIC_25","Inclusion Criteria:\n\n* Healthcare professionals (physicians, nurses and healthcare assistants\u002FOSS) employed in the Cardiac Intensive Care Unit (UTIC) of the University Hospital of Parma.\n* Healthcare professionals who have completed the training pathway and are still working in the unit at the time of the six-month follow-up.\n* Medical and nursing students who have carried out or are carrying out a clinical placement within the UTIC.\n* Ability to use a computer or mobile device, essential for participating in the online training activities (e.g. Moodle, H5P).\n* Provision of written informed consent before initiation of any study procedure.\n\nExclusion Criteria:\n\n* Healthcare professionals who do not work in the cardiology setting or who are not employed in the UTIC of the AOU Parma.\n* Inability to participate in the training activities or assessment sessions for logistical, organisational or clinical reasons (e.g. planned prolonged absences during the study period).\n* Refusal or inability to provide informed consent.",true,{"count":170,"type":21},60,[24],"This study evaluates the impact of a structured interprofessional training program on daily collaboration within the Cardiac Intensive Care Unit (CICU\u002FUTIC) at the University Hospital of Parma. In high-intensity clinical settings, rapid and accurate coordination between physicians, nurses, and healthcare assistants is vital. Ineffective teamwork often leads to communication breakdowns, potentially compromising patient safety and care quality. This project investigates whether an interactive, scenario-based educational program can strengthen role clarity, communication, and shared decision-making.\n\nThe study seeks to determine if an active-learning program using interactive branching scenarios improves interprofessional collaboration more effectively than traditional methods. The researchers hypothesize that this simulation-based approach will significantly enhance professional outcomes, including self-efficacy, shared decision-making, and commitment to both the team and the profession.\n\nThe study utilizes a convenience sample (approx. 5 physicians, 30 nurses, 8 healthcare assistants, and 10 students). Eligible participants include staff and students currently or recently active in the Parma CICU who provide informed consent.\n\nThe intervention is delivered via a Moodle-based platform featuring case-based simulations. These scenarios replicate complex clinical pathways, such as:\n\nCath-lab and Electrophysiology procedures.\n\nHeart failure management.\n\nTAVI (Transcatheter Aortic Valve Implantation) preparation.\n\nAs participants navigate these scenarios, they must make critical decisions and receive immediate feedback designed to reinforce collaborative best practices.\n\nData Collection and Timeline\n\nData is gathered at three intervals: T0 (Baseline), T1 (Post-training), and T2 (6-month follow-up). Validated questionnaires measure:\n\nAttitudes toward physician-nurse collaboration.\n\nPerceived daily collaboration and decision-making satisfaction.\n\nProfessional commitment and work-related self-efficacy.\n\nThe training phase spans six months, with a subsequent six-month follow-up, totaling a 24-month project duration.\n\nEthics and Privacy Risks are minimal, primarily involving the time required for participation. The primary benefit is the development of skills that foster safer, more coordinated patient care. Privacy is strictly maintained through pseudo-anonymization, with data access restricted to the research team.",[174,175,176,177,178],"Interprofessional Relations","Interprofessional Education","Attitude of Health Personnel","Intensive Care Units","Critical Care",[174,180,181,182,177,183,178,184,185,186],"Interdisciplinary Communication","Health Personnel Attitudes","Nurse-Physician Relations","Coronary Care Units","Patient Care Team","Education, Interprofessional","Clinical Decision-Making","NOT_YET_RECRUITING","2026-01-14",{"date":190,"type":44},"2026-01-22",{"date":192,"type":21},"2026-02-15",{"date":194,"type":21},"2028-02-15",{"name":50,"class":51},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":204,"targetDuration":206,"studyType":207,"phases":4,"briefSummary":208,"conditions":209,"keywords":212,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":79},"100385536","italian-multicenter-database-for-open-conversions-after-evar-100385536","NCT04299984","Italian Multicenter Database for Open Conversions After EVAR","Italian Multicenter Prospective Database for Open Conversions and SemiConversions After Endovascular Aneurysm Repair","iConveRt","Inclusion Criteria:\n\n* open or laparoscopic surgery for EVAR complications, with or without endograft explantation\n\nExclusion Criteria:\n\n* endovascular reinterventions\n* extra-anatomical bypass surgery (e.g. femoro-femoral crossover bypass) not associated with direct aorta\u002Fendograft surgery",{"count":205,"type":21},500,"5 Years","OBSERVATIONAL","Late endovascular abdominal aneurysm repair (EVAR) complications not amenable to endovascular correction can undergo either late open conversion (LOC) or semi-conversion (SC).\n\nLOC is defined as a total or partial endograft explantation \\>30 days after the initial EVAR.\n\nSC is defined as open or laparoscopic surgery for endoleak (EL) correction with complete endograft preservation.\n\nThe aim of this study is to collect in a prospective database the technical aspects of a multicenter experience of LOC and SC, and to analyse early and long-term outcomes of these two treatments.",[210,211],"Abdominal Aortic Aneurysm","Abdominal Aortic Aneurysm Enlargement",[213,214,215,216,217],"Abdominal aortic aneurysm","Open surgical conversion","Endovascular repair","EVAR explantation","Failed EVAR","2025-05-29",{"date":220,"type":44},"2025-06-04",{"date":222,"type":44},"2022-01-01",{"date":224,"type":21},"2032-12-31",{"name":50,"class":51},{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":168,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":79},"100584348","food-polyphenol-metabotypes-and-beta-cell-mass-and-function-100584348","NCT06888167","Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.","Experimental, Drug-free, Cross-sectional, Single-centre Study to Assess the Association Between Metabotypes of Dietary (Poly)Phenols and Beta-cell Mass and Function.","META-BETA","Inclusion Criteria:\n\n* Having been enrolled in the OPCT study;\n* Ability to understand the methods, purposes and implications of the study, and to give free and informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding;\n* Previous exposure to ionizing radiation in research programs;\n* History of psychiatric illness or alcohol abuse;\n* Head trauma;\n* Active neurological disease;\n* Claustrophobia;\n* Active malignant neoplastic disease.",{"count":235,"type":21},40,[24],"Cross-sectional, single-centre, 'low intervention' clinical study, without drug or medical device testing, with low-risk diagnostic technique.",[239],"Healthy Volunteer","2025-03-14",{"date":242,"type":44},"2025-03-21",{"date":244,"type":44},"2024-10-14",{"date":246,"type":21},"2026-02-28",{"name":50,"class":51},{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":59,"minAge":18,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":258,"briefSummary":259,"conditions":260,"keywords":265,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":79},"100490135","assessment-of-pancreatic-beta-cell-mass-and-function-by-positron-emission-tomography-imaging-in-human-diabetes-mellitus-100490135","NCT05662189","Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus","Assessment of Pancreatic Beta Cell Mass and Function with the Aid of Positron Emission Tomography Imaging in Human Diabetes Mellitus","Inclusion Criteria:\n\n* Age ≥18 years; ≤ 75 years\n* Both sexes\n* Good health\n* Absence of exclusion criteria\n* Able to understand methods, goals, and implications of the research and of delivering a free, written informed consent\n\nExclusion Criteria:\n\n* Hemoglobin \\\u003C 12 g\u002Fdl\n* HbA1c \\> 10%\n* Pregnancy or breast-feeding\n* If not in menopause, women not using effective birth control methods or not willing to undergo a pregnancy test\n* History of severe psychiatric disorder or alcohol abuse\n* Recent head traumas (\\\u003C6 months)\n* Active neurologic diseases\n* Claustrophobia\n* Active malignant neoplasms\n* Severe kidney and\u002For liver disease\n* Recent (\\\u003C6 months) major adverse cardiovascular events\n* Heart failure (class NYHA 3-4)\n* Drugs known to affect beta cell function and\u002For insulin sensitivity\n* Current or past treatment with GLP1R-agonists\n* Intolerance to exenatide\n* Endocrine diseases, other than diabetes mellitus, known to affect beta cell function and\u002For insulin sensitivity, except well controlled hypothyroidism or adrenal insufficiency\n* COPD on day time oxygen therapy\n* Any current acute disease","75 Years",{"count":257,"type":21},70,[24],"The goals of this project are to build an experimental tool to dissect out in vivo pancreatic beta cell mass (BCM) and beta cell function (BCF) and to assess for the first time these two determinants of beta cell functional mass (BCFxM) in obesity and in various stages of type 1 and type 2 diabetes mellitus.",[261,262,263,264],"Type1diabetes","Type2diabetes","Pre Diabetes","Hyperinsulinism",[266,267,268,269],"diabetes","beta-cell","exendin","PET-CT",{"date":271,"type":44},"2025-03-18",{"date":273,"type":44},"2022-03-15",{"date":275,"type":21},"2025-12",{"name":50,"class":51},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":299},"100564262","integrative-omics-approaches-for-leukemia-target-identification-and-matched-therapeutic-intervention-100564262","NCT06626893","Integrative \"Omics\" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention","AL-TOMICA","Inclusion Criteria:\n\n* Patients to be enrolled in the study must have a diagnosis of AML, B ALL\u002FLBL, T ALL\u002FLBL, MPAL\u002FAUL as described by WHO 2016 classification and must complained relapsed or refractory disease after at least one line of therapy\n* Ages Eligible for Study: over 18years\n* Patients must have greater than 5% blasts in the bone marrow with or without extramedullary disease\n* Patients with must have recurrent disease, documented by clinical or radiographic criteria, as well as histologic verification of the malignancy at original diagnosis\n* Patients may be enrolled on study regardless of the timing of prior I therapy\n* Patients must be capable of understanding the investigational nature and the objectives of the study. All patients must sign a written informed consent.\n\nExclusion Criteria:\n\n\\-",{"count":285,"type":21},100,[24],"The goal of this clinical trial is to use multiple \"omics\" sciences to more thoroughly investigate Acute Recurrent\u002FRefractory Leukemias (LA R\u002FR) after conventional therapy in order to identify new targets and\u002For therapeutic approaches, in patients with a diagnosis of Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia\u002F Lymphoblastic Lymphoma B(ALL-B), Acute Lymphoblastic Leukemia\u002FLymphoblastic Lymphoma T (ALL-T), Acute Biphenotypic Leukemia\u002FII as defined by WHO( World Health Organization) 2016, relapsed or refractory after at least one line of therapy. The main question that the trial aims to answer is: \"Can molecules with known biological activity be active and represent possible new therapeutic strategies in relapsed\u002Frefractory Acute Leukemias on the basis of response profiles identified through the integration of next-generation chemogenomic and functional analyses? \" It is expected that a minimum of 100 patients, male and female, aged 18 years and older, will be included. To participate in the study, the patient must consent to the performance on biological specimen (peripheral blood and bone marrow) of genetic\u002Fmolecular and\u002For \"omics\" investigations performed with modern sequencing techniques, such as Next Generation Sequencing, Single Cell RNA Seq (scRNAseq), RT-qPCR(Quantitative reverse transcription polymerase chain reaction). These investigations will aim to improve the understanding of the genetic and molecular alterations of her disease. In addition, your cells will be used in the laboratory to perform in vitro sensitivity studies (drug response profiling - DRP) that aim to simultaneously test a set of hundreds of drugs to assess sensitivity or resistance profiles of your disease cells with the aim of identifying specific new therapies that target specific cellular mechanisms. In addition, part of the biological sample will be used for investigations of the bone marrow microenvironment and the \"secretome\", i.e., cell signaling molecules and methods. In order to accomplish this study, samples from peripheral or bone marrow blood taken during routine investigations performed during follow-up and re-evaluation visits for the patient's disease as per normal clinical practice will be used. Among the investigations that will be performed on the blood sample will be the genetic\u002Fmolecular and\u002For omics and preclinical investigations described above.",[289,290],"Myeloid Leukemia, Acute","Leukemia, Acute Lymphoblastic","2024-10-02",{"date":293,"type":44},"2024-10-04",{"date":295,"type":44},"2022-03-01",{"date":297,"type":21},"2025-03-01",{"name":50,"class":51},8,{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":207,"phases":4,"briefSummary":310,"conditions":311,"keywords":322,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":299},"100551962","evaluation-of-intra-operative-photographs-for-the-assessment-of-a-proper-lymphadenectomy-in-minimally-invasive-gastrectomies-for-gastric-cancer-photonodes-100551962","NCT06466902","Evaluation of Intra-operative Photographs for the Assessment of a Proper Lymphadenectomy in Minimally-invasive Gastrectomies for Gastric Cancer (PhotoNodes)","Evaluation of Intra-operative Photographs for the Assessment of a Proper Lymphadenectomy in Minimally-invasive Gastric Cancer Surgery (PhotoNodes)","PhotoNodes","Inclusion Criteria:\n\n* All patients undergoing minimally invasive curative-intent surgery for gastric adenocarcinoma with D2 lymphadenectomy\n* Patients undergoing upfront surgery or treated with a neoadjuvant\u002Fperioperative chemotherapy\n* Total or Subtotal Gastrectomy\n* Laparoscopic or Robotic approach\n\nExclusion Criteria:\n\n* Age less than 18 year old\n* Esophago-gastric junction cancer Siewert type I, II or III\n* Metastatic disease\n* Lymphadenectomy less than D2\n* Open surgery\n* Conversion to open surgery\n* Palliative gastrectomy\n* R1 or R2 resection\n* Multivisceral resection except for cholecystectomy\n* Surgical procedures other than subtotal or total gastrectomy\n* A single node station rated as unevaluable by more than one reviewer",{"count":309,"type":21},326,"Even after the wide introduction of chemo\u002Fradiotherapy in the treatment algorithm, adequate surgery remains the cornerstone of gastric cancer treatment with curative intent. A proper D2 lymphadenectomy is associated with improved cancer specific survival as confirmed in Western countries by fifteen-year follow-up results of Dutch and Italian randomized trials.\n\nIn clinical practice, the total number of harvested lymph nodes is often considered as a surrogate marker for adequate D2 lymphadenectomy; nonetheless, the number of retrieved nodes does not necessarily correlate with residual nodes, which intuitively could represent a more reliable marker of surgical adequacy. The availability of an efficient tool for evaluating the absence of residual nodes in the operative field at the end of node dissection could better correlate with survival outcomes.\n\nThe goal of this multicentric observational prospective study is to test the reliability of a new score (PhotoNodes Score) created to rate the quality of the lymphadenectomy performed during minimally invasive gastrectomy for gastric cancer. The score is assigned by assessing the absence of residual nodes at the end of node dissection on a set of laparoscopic\u002Frobotic high quality intraoperative images collected from each patient undergoing a minimally invasive gastrectomy with D2 node dissection.\n\nIdeally, this tool could be a new indicator of the quality of D2 dissection and could assume a prognostic role in the treatment of gastric cancer.",[312,313,314,315,316,317,318,319,320,321],"Gastric Cancer","Gastric Adenocarcinoma","Lymphadenectomy","Minimally Invasive Surgery","Gastrectomy for Gastric Cancer","Laparoscopic Surgery","Robotic Surgery","Survival Outcomes","Survival Analysis","Quality Of Care",[323,324],"D2 Lymphadenectomy quality assessment","Minimally invasive gastric cancer oncologic surgery","2024-07-03",{"date":327,"type":44},"2024-07-05",{"date":329,"type":44},"2022-12-22",{"date":331,"type":21},"2027-12",{"name":50,"class":51},{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":59,"minAge":18,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":207,"phases":4,"briefSummary":343,"conditions":344,"keywords":347,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":360},"100162231","computed-tomography-coronary-angiography-ctca-prognostic-registry-for-coronary-artery-disease-100162231","NCT01384721","Computed Tomography Coronary Angiography (CTCA) Prognostic Registry for Coronary Artery Disease","Computed Tomography Coronary Angiography Prognostic Registry for Coronary Artery Disease - CTCA-PRORECAD","PRORECAD","Inclusion Criteria:\n\n* Only patients with also Calcium Score\n* ≥64-slice CT technology (or 16-slice CT technology with \\>4 year follow-up)\n* Number of patients of at least 100 with complete clinical file and follow-up\n* Minimum follow-up of 12 months\n* Only patients with suspected Coronary Artery Disease\n\nExclusion Criteria:\n\n* renal failure (creatinine clearance \\\u003C60ml\u002Fmin)\n* known previous reaction to iodinated contrast medium and pregnancy\n* history of Myocardial Infarction\n* previous revascularization (PCI and\u002For CABG)",{"count":342,"type":21},1000,"The study aims at pooling a large population of patients with suspected coronary artery disease (CAD) who underwent Computed Tomography Coronary Angiography (CTCA) and who were adequately stratified in the first place. Then the investigators will be able to assess the incremental value of CTCA in the stratification of prevalence of disease (non obstructive\u002Fobstructive) and prognosis of patients with suspected CAD). The added information to current evidence is how reliable and to what extent CTCA can define the actual burden of disease and cardiovascular risk.",[345,346],"Coronary Artery Disease","Atherosclerosis",[348,345,349,350,351],"Computed Tomography Coronary Angiography","Prevalence Of Disease","Prognosis","Risk Stratification","2021-01-12",{"date":354,"type":44},"2021-01-13",{"date":356,"type":4},"2010-09",{"date":358,"type":21},"2028-09",{"name":50,"class":51},11,""]